What should define a SARS-CoV-2 "breakthrough" infection?
作者信息
Schieffelin John S, Norton Elizabeth B, Kolls Jay K
机构信息
Tulane Department of Pediatrics.
Tulane Department of Microbiology and Immunology, and.
出版信息
J Clin Invest. 2021 Jun 15;131(12). doi: 10.1172/JCI151186.
Abstract
摘要
相似文献
1
What should define a SARS-CoV-2 "breakthrough" infection?什么应该定义为新冠病毒的“突破性”感染？
J Clin Invest. 2021 Jun 15;131(12). doi: 10.1172/JCI151186.
2
SARS-CoV-2 infection confers greater immunity than shots.感染新冠病毒所产生的免疫力强于接种疫苗。
Science. 2021 Sep 3;373(6559):1067-1068. doi: 10.1126/science.acx8993. Epub 2021 Sep 1.
3
[Vaccination immunology in SARS-CoV-2].[新型冠状病毒肺炎中的疫苗接种免疫学]
Ugeskr Laeger. 2021 Mar 15;183(11).
4
Mucosal antibody responses to SARS-CoV-2 booster vaccination and breakthrough infection.黏膜抗体对 SARS-CoV-2 加强针接种和突破感染的反应。
mBio. 2023 Dec 19;14(6):e0228023. doi: 10.1128/mbio.02280-23. Epub 2023 Dec 1.
5
Special focus 'SARS-CoV-2 / COVID-19: advances in developing vaccines and immunotherapeutics'.特别关注“SARS-CoV-2 / COVID-19：疫苗和免疫疗法研发进展”
Hum Vaccin Immunother. 2020 Dec 1;16(12):2888-2890. doi: 10.1080/21645515.2020.1847952.
6
Influenza Virus and SARS-CoV-2 Vaccines.流感病毒和 SARS-CoV-2 疫苗。
J Immunol. 2021 Jun 1;206(11):2509-2520. doi: 10.4049/jimmunol.2001287. Epub 2021 May 21.
7
Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.黏膜疫苗对恒河猴感染 SARS-CoV-2 的保护作用。
JCI Insight. 2021 Apr 28;6(10):148494. doi: 10.1172/jci.insight.148494.
8
T cell immunity to SARS-CoV-2 following natural infection and vaccination.自然感染和接种疫苗后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的T细胞免疫
Biochem Biophys Res Commun. 2021 Jan 29;538:211-217. doi: 10.1016/j.bbrc.2020.10.060. Epub 2020 Oct 23.
9
Vaccine against SARS-CoV-2 in previously infected health care workers.曾感染过新冠病毒的医护人员接种新冠病毒疫苗。
EBioMedicine. 2021 Sep;71:103556. doi: 10.1016/j.ebiom.2021.103556. Epub 2021 Aug 26.
10
Intranasal COVID-19 vaccines: From bench to bed.鼻内 COVID-19 疫苗：从实验室到临床。
EBioMedicine. 2022 Feb;76:103841. doi: 10.1016/j.ebiom.2022.103841. Epub 2022 Jan 24.
引用本文的文献
1
Updated Considerations for the Immunopharmacological Aspects of the "Talented mRNA Vaccines".“卓越信使核糖核酸疫苗”免疫药理学方面的最新考量
Vaccines (Basel). 2023 Sep 12;11(9):1481. doi: 10.3390/vaccines11091481.
2
Breakthrough infections due to SARS-CoV-2 Delta variant: relation to humoral and cellular vaccine responses.SARS-CoV-2 德尔塔变异株引起的突破性感染：与体液和细胞疫苗应答的关系。
Front Immunol. 2023 Mar 30;14:1145652. doi: 10.3389/fimmu.2023.1145652. eCollection 2023.
3
Severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections: A single metro-based testing network experience.严重急性呼吸综合征冠状病毒2型疫苗突破性感染：基于单一城市的检测网络经验
Front Med (Lausanne). 2022 Nov 25;9:1031083. doi: 10.3389/fmed.2022.1031083. eCollection 2022.
4
Assessment of SARS-CoV-2 vaccination status in SARS-COV-2 infected patients admitted in Dr Ruth K.M. Pfau, Civil Hospital Karachi.对卡拉奇市民医院鲁思·K·M·普法夫医生收治的新冠病毒感染患者的新冠病毒疫苗接种状况评估。
Pak J Med Sci. 2022 Nov-Dec;38(8):2089-2094. doi: 10.12669/pjms.38.8.5733.
5
Simulation applications to support teaching and research in epidemiological dynamics.模拟应用支持流行病学动力学的教学和研究。
BMC Med Educ. 2022 Aug 20;22(1):632. doi: 10.1186/s12909-022-03674-3.
6
High viral loads: what drives fatal cases of COVID-19 in vaccinees? - an autopsy study.高病毒载量：是什么导致了疫苗接种者 COVID-19 的致命病例？——一项尸检研究。
Mod Pathol. 2022 Aug;35(8):1013-1021. doi: 10.1038/s41379-022-01069-9. Epub 2022 Apr 1.
7
Engineering monoclonal antibodies for COVID-19 prophylaxis.用于 COVID-19 预防的工程单克隆抗体。
Med. 2022 Mar 11;3(3):157-158. doi: 10.1016/j.medj.2022.02.004.
8
Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs.剖析新冠病毒突破性感染对新冠疫苗接种计划的影响
Vaccines (Basel). 2022 Feb 7;10(2):252. doi: 10.3390/vaccines10020252.
9
SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review.接种新冠疫苗的医护人员中出现的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）信使核糖核酸（mRNA）疫苗突破性感染：一项系统综述
Trop Med Infect Dis. 2022 Jan 13;7(1):9. doi: 10.3390/tropicalmed7010009.
10
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant.关于 SARS-CoV-2 德尔塔变异株疫苗突破性感染的系统评价。
Int J Biol Sci. 2022 Jan 1;18(2):889-900. doi: 10.7150/ijbs.68973. eCollection 2022.
本文引用的文献
1
Vaccine Breakthrough Infections with SARS-CoV-2 Variants. Reply.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变异株的疫苗突破性感染。回复。
N Engl J Med. 2021 Jul 8;385(2):e7. doi: 10.1056/NEJMc2107808. Epub 2021 Jun 2.
2
Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021.疫苗接种后，熟练护理机构居民和工作人员中的 SARS-CoV-2 感染 - 伊利诺伊州芝加哥，2020 年 12 月至 2021 年 3 月。
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):632-638. doi: 10.15585/mmwr.mm7017e1.
3
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.BNT162b2 疫苗和 mRNA-1273 新冠疫苗在预防医护人员、第一响应者和其他必要及一线工作人员感染 SARS-CoV-2 中的疫苗有效性的临时估计-2020 年 12 月至 2021 年 3 月美国 8 个地点。
MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3.
4
SARS-CoV-2 Infection after Vaccination in Health Care Workers in California.加利福尼亚州医护人员接种疫苗后感染新冠病毒
N Engl J Med. 2021 May 6;384(18):1774-1775. doi: 10.1056/NEJMc2101927. Epub 2021 Mar 23.
5
Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center.一家医疗中心关于新冠病毒疫苗效果的早期证据。
N Engl J Med. 2021 May 20;384(20):1962-1963. doi: 10.1056/NEJMc2102153. Epub 2021 Mar 23.
6
Five reasons why COVID herd immunity is probably impossible.新冠病毒群体免疫可能无法实现的五个原因。
Nature. 2021 Mar;591(7851):520-522. doi: 10.1038/d41586-021-00728-2.
7
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.一剂接种和加强针接种时间对 ChAdOx1 nCoV-19（阿斯利康）疫苗免疫原性和有效性的影响：四项随机试验的 pooled 分析。
Lancet. 2021 Mar 6;397(10277):881-891. doi: 10.1016/S0140-6736(21)00432-3. Epub 2021 Feb 19.
8
Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.Ad26.COV2.S 新冠疫苗 1/2a 期临床试验的中期结果。
N Engl J Med. 2021 May 13;384(19):1824-1835. doi: 10.1056/NEJMoa2034201. Epub 2021 Jan 13.
9
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
10
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
Zotero 插件